Aquestive Therapeutics (AQST) has secured US Food and Drug Authority (FDA) approval for its drug, Exservan, for the treatment of amyotrophic lateral sclerosis (ALS), or motor neuron disease, according to FDA website.

In April, the FDA accepted its New Drug Application for the investigational product riluzole oral film as an adjunctive therapy in the treatment of ALS. It plans to market the drug under the brand name Exservan.